GSK4524101, Niraparib — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-06-30 in 8d
ESTIMATED |
READOUT
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Prel
Phase 1/2 · Neoplasms |
GlaxoSmithKline | GSK4524101, Niraparib |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|